47 Result(s)
within
Constantin N. Baxevanis
-
Article
Open AccessProspective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence
AE37 and GP2 are HER2 derived peptide vaccines. AE37 primarily elicits a CD4+ response while GP2 elicits a CD8+ response against the HER2 antigen. These peptides were tested in a large randomized trial to asse...
-
Article
The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer
Tumors and their surrounding area represent spatially organized “ecosystems”, where tumor cells and the immune contextures of the different compartments are in a dynamic interplay, with potential clinical impa...
-
Article
The role of immune infiltrates as prognostic biomarkers in patients with breast cancer
The presence of immune infiltrates in the tumor microenvironment has been documented in many types of cancer. Moreover, the preexistent or endogenous immunity which consists of interactions between intratumora...
-
Article
4th Symposium on Advances in Cancer Immunology and Immunotherapy, November 29–December 1, 2018, Athens, Greece
-
Article
T-cell recognition of non-mutated tumor antigens in healthy individuals: connecting endogenous immunity and tumor dormancy
The concept of a dual functional programme of the immune system to destroy malignant cells but also to edit their immunogenic profile, considerably improved our understanding of the process of tumor evolution ...
-
Article
Serum miRNA-based distinct clusters define three groups of breast cancer patients with different clinicopathological and immune characteristics
Breast cancer (BCa) is a heterogeneous disease with different histological, prognostic and clinical aspects. Therefore, the need for identification of novel biomarkers for diagnosis, prognosis and monitoring o...
-
Article
2nd Symposium on Advances in Cancer Immunology and Immunotherapy, December 15–17, 2016, Athens, Greece
This is the 2nd Symposium of a series organized annually. It aims to integrate tumor immunology basic research with results from most recent clinical trials based on the use of anti-cancer agents targeting imm...
-
Article
Immune profiling of melanoma tumors reflecting aggressiveness in a preclinical model
Melanoma, like most solid tumors, is highly heterogeneous in terms of invasive, proliferative, and tumor-initiating potential. This heterogeneity is the outcome of differential gene expression resulting from c...
-
Article
Open AccessErratum to: Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer
-
Article
Open AccessDifferential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer
Tumor immune cell infiltrates are essential in hindering cancer progression and may complement the TNM classification. CD8+ and CD163+ cells have prognostic impact in breast cancer but their spatial heterogene...
-
Article
Peripheral T cell responses to tumour antigens are associated with molecular, immunogenetic and cellular features of breast cancer patients
Breast cancer is a leading cause of cancer deaths in women, but despite steady improvements in therapies, treatment is still suboptimal. Immunotherapy holds promise as a more effective therapy for breast cance...
-
Article
Open AccessUnraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide
Cancer vaccines aim at eliciting not only an immune response against specific tumor antigens, but also at enhancing a preexisting immunity against the tumor. In this context, we recently reported on the levels...
-
Article
Open AccessImmune profiling of breast cancer patients: relationship between tumour antigen T cell responses with suppressor and effector leukocyte populations
-
Article
Open AccessDRB1*11 allele expression and HER2 pre-existing immunity may predict benefit in breast cancer patients vaccinated with the HER2 modified AE37 peptide vaccine
-
Article
A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit
Recently, several types of immunotherapies have been shown to induce encouraging clinical results, though in a restricted number of patients. Consequently, there is a need to identify immune biomarkers to sele...
-
Article
Prostate cancer vaccines: the long road to clinical application
Cancer vaccines as a modality of immune-based cancer treatment offer the promise of a non-toxic and efficacious therapeutic alternative for patients. Emerging data suggest that response to vaccination largely ...
-
Article
AE37 peptide vaccination in prostate cancer: identification of biomarkers in the context of prognosis and prediction
A fundamental challenge in administering immunotherapies for cancer is the establishment of biomarkers that can predict patients’ responsiveness to treatment. In this study, our aim was to predict the immunolo...
-
Protocol
Invariant Chain-Peptide Fusion Vaccine Using HER-2/neu
A novel method for amplifying the activity of major histocompatibility complex (MHC) class II helper epitopes entails linking a 4-amino-acid moiety (LRMK) from the invariant chain (Ii) of MHC (referred to as I...
-
Article
AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial
In our recent phase I trial, we demonstrated that the AE37 vaccine is safe and induces HER-2/neu-specific immunity in a heterogeneous population of HER-2/neu + prostate cancer patients. Herein, we...
-
Article
Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice
Disrupting tumor-mediated mechanisms suppressing host immunity represents a novel approach to tumor immunotherapy. Depletion of regulatory T cells (Tregs) increases endogenous anti-tumor immunity and the effic...
